# A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

> **NCT03158103** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor (GIST)

## Interventions

- **DRUG:** MEK162
- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT03158103
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-15
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158103, "A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03158103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*